Wehrmedizinische Monatsschrift

  • Archiv
  • Kontakt
  • Archiv
  • Kontakt

Suchergebnis
Links
Rechts
Inhaltsverzeichnis
Editorial
Rekonstruktive Chirurgie
Die Plastische Chirurgie im wehrmedizinischen Kontext








Digitalisierung
Von klinischer Kommunikation bis zukünstlicher Intelligenz – zum Nutzen von „Apps“


Das Online-Angebot von WINGLET – Erfahrungen mit der Nutzung am Bundeswehrkrankenhaus Berlin (Poster-Abstract)
Orthopädie /​ Unfallchirurgie
Seltene Lokalisation eines Chondrosarkoms im unteren Sitzbeinast – ein Fallbericht

Der besondere Fall:​ Segmenttransport über einen neuen intramedullären motorisierten Transportnagel (Vortragsabstract)

Dynamische intraligamentäre Stabilisierung (DIS) von Rupturen des vorderen Kreuzbandes – ein Benefit für Patient und Bundeswehr?

Infektiologie meets Orthopädie/​Unfallchirurgie – Case Report einer tuberkulösen Arthritis (Poster-Abstract)

Neurochirurgie
Zur Einsatzrelevanz neurochirurgischer Fachkenntnis vor Ort:​ Gefechtsbedingte neurotraumatologische Verletzungsmuster in Afghanistan 2014 und 2018 (Vortrags-Abstract)

Polytrauma und schweres Schädel-Hirn-Trauma überlebt – und dann? (Vortrags-Abstract)
Einsatzmedizin
Zurück in die Vergangenheit? Hämotherapie der akuten Hämorrhagie des Verwundeten
Internationale Zusammenarbeit
Translationale Phagenforschung:​ Wiederentdeckte Potenziale wissenschaftsbasiert zur Prävention und Therapie von Infektionen mit multiresistenten Erregern nutzen


The US Army Bacteriophage Therapeutics Program for the Treatment of Multidrug Resistant Wound Infections
Luft- und Raumfahrtmedizin
Inzidentelle Befunde im Fachgebiet Neurologie und flugmedizinische Erwägungen bei aktiv fliegendem Personal

Aus dem Sanitätsdienst
ZUM 80.​ GEBURTSTAG
ZUM 75.​ GEBURTSTAG
Mitteilungen der DGWMP e.​ V.​
Geburtstage Juli und August 2020
Oberstarzt Prof.​ Dr.​ Heinz Gerngroß (2.​ Juli 1947 - 2.​ Juni 2005)
PDF

The US Army Bacteriophage Therapeutics Program
for the Treatment of Multidrug Resistant Wound Infections

Brett Swierczewski a, Andrey Filippov a, Anna Jacobs a, Yunxiu He a, Amanda Ward a, Helen Freyberger a,
Emily Engeman a, Samandra Demons a, Derese Getnet a, Stuart Tyner a, and Mikeljon Nikolich a

 

New solutions for military relevant bacterial ­infections

Wound infections caused by multidrug resistant (MDR) Gram-negative bacteria to include the ESKAPE pathogens ( E nterococcus faecium, S taphylococcus aureus, K lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa , and E nterobacter spp) are a persistent challenge as antibiotic treatment options become limited and the development of new antibiotics more rare [1]. As combat wounds are characterized by penetrating trauma and foreign body inocula, the increase of ­ESKAPE pathogens in complicated MDR combat-related wound infections to include burns and fractures are of particular concern as variants have emerged with resistance to carbapenems which are typically last line treatment. It is estimated that over 52,000 U. S. service members were wounded during Operations Enduring Freedom and Iraqi Freedom (OEF and OIF) and that 49 % of those wounded had bacteria within their wounds, 34 % of combat casualties developed MDR bacterial infections during their initial hospitalization [3]. Due to the rise on these resistant bacterial infections, the U.S. Army began to explore alternative therapeutics besides antibiotics for treatment of MDR combat wound infections.

The exploration of new alternative therapeutics to include the use of bacteriophages, viruses that infect, replicate and kill bacteria, is of critical importance for treating MDR wound infections. The use of bacteriophages for the treatment of bacterial infections has been used for over a century, but only recently has their use reemerged to the international medical community as there have been sev eral recent cases of success of the use of bacteriophages for the treatment of MDR infections [2][5].

Bacteriophage cocktails in development for ­treatment and prevention

The Wound Infections Department (WID) located within the Bacterial Diseases Branch at WRAIR 1 has implemented a rational design strategy for the development of durable, fixed bacteriophage cocktails that can be used as both – therapies in combination with conventional antibiotic drugs or as preventatives to treat and prevent MDR infections that afflict U.S. Military service members during deployment and combat. This was in direct response to the significant increase in MDR wound infections seen in U .S. service members wounded in OIF and OEF. Additionally, international health agencies consider antimicrobial resistance (AMR) to be an immediate threat to human health. Antibiotic overuse, misuse and globalization have accelerated the emergence of multidrug resistant organisms on every continent and that far too little progress has been made to reverse the AMR pandemic.

The main thrust of WRAIR’s effort in recent years has been focused on the development of standardized, durable bacteriophage cocktails for the treatment of MDR P. aeruginosa and K. pneumoniae respectively .

Durable phage cocktail design components

Bacteriophages were all isolated from raw sewage, environmental and soil sources located in the greater Washington DC area. Individual bacteriophage characterization included the following steps: (1.) Isolation and Purification, (2.) Genomic Analysis (whole genome sequencing), (3.) Lytic Kinetics, ( 4.) Host Range/Spectrum, (5.) Morphology (electron microscopy), (6.) Anti- biofilm activity, (7.) Resistance Rate, (8.) Receptor(s), (9.) Phage- Phage Interactions, (10.) Antibiotic Synergy, (11.) Production and Stability, and ( 12.) Phage Cocktail Formulation (Figure 1). Phages are selected based on high lytic activity, anti-biofilm activity, broad host range, phylogenetic diversity, safe gene content in genomic analysis, host receptor diversity, and stability/compatibility in mixes.

Brett_Figure_1_(1)

Figure 1: From raw sewage, environmental and soil sources to a usable phage cocktail formulation: The Phage Pipeline

Rational design approach for fixed therapeutic ­phage cocktail development

To date, over 200 phages meeting the criteria above have been isolated against P. aeruginosa, K. pneumoniae, S. aureus, E. cloacae, and also for the diarrheal pathogen, Shigella spp. Bacteriophages are tested for lytic activity in vitro via plaque assays against a global diversity panel of the above bacteria respectively provided by Multidrug Resistant Organism Repository and Surveillance Network located at WRAIR [4]. Two phage cocktails for P. aeruginosa are the most advanced showing high levels of lytic activity against P. aeruginosa clinical isolates and 100 % protection in a pre-clinical mouse septicemia model.

Utilise experience from eIND for clinical development

Custom cocktails from the P. aeruginosa phage collection at WRAIR have been produced and have been used in two Emergency Investigational New Drug (eIND) cases in patients with pan resistant P. aeruginosa infections. Due to the lack of randomized clinical trials (RCTs) for bacteriophage therapy, participation in eIND cases is helpful in gaining critical information about phage therapy, but are not replacements for a sufficiently powered RCT.

In conclusion, the development of broad-based, fixed phage cocktails will continue to be pursued and refined for the treatment of combat wound infections. The continued development of bacteriophage candidates and the testing of these cocktails in randomized clinical trials will enable physicians, researchers and outbreak response teams to effectively treat MDR wound infections in the future.

Setting  up a collaboration with the Bundeswehr Institute of Microbiology

At the first “Phage Meeting” organized by the Bundes­wehr Hospital Berlin in December 2019 initial contact was made between the WRAIR phage therapy group and the Bundeswehr Institute of Microbiology (IMB ). This was followed by a visit to WRAIR, as a part of a visit of the new IMB director. At this occasion possibilities to support the development of bacteriophage therapeutics against MDR bacteria were discussed. Currently the process of setting up a collaboration focusses on infections with K. pneumoniae of Type 4 MRGN. An exchange of material and personel, joint publications, as well as more formal collaboration between the institutions are planned for 2020/2021.

References

  1. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR: Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front Microbiol. 2019; 10: 539. mehr lesen
  2. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L et al.: Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017;61(10): e00954-17. Erratum: Antimicrob Agents Chemother. 2018; 62(12): e02221-18 mehr lesen
  3. Tribble DR, Murray CK, Lloyd BA, Ganesan A, Mende K, Blyth DM, Petfield JL, McDonald J: After the Battlefield: Infectious Complications among Wounded Warriors in the Trauma Infectious Disease Outcomes Study. Mil Med. 2019 Nov 1; 184(Supplement_2): 18-25. mehr lesen
  4. Waterman P, Kwak Y, Clifford R, Julius M, Onmus-Leone F, Tsurgeon C et al.: A multidrug-resistance surveillance network: 1 year on. Lancet Infect Dis. 2012; 12(8): 587. mehr lesen
  5. Wittebole X, De Roock S, Opal SM: A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014; 5(1): 226-235. mehr lesen

For the authors
Brett E. Swierczewski, PhD – LTC, US Army
Director
, Bacterial Diseases Branch (BDB) Center for Military Infectious Disease Research (CIDR) Walter Reed Army Institute of Research (WRAIR)
503 Robert
Grant Ave, Silver Spring, Maryland, USA
E-Mail:
brett.e.swierczewski.mil@mail.mil


1The Walter Reed Army Institute of Research (WRAIR) located in Silver Spring, Maryland, United States, is the largest biomedical research facility administered by the U.S. Department of Defense (DoD) and aims to conduct biomedical research that is responsive to DoD and US Army requirements. WRAIR’s mission is to discover, design, and develop solutions for military relevant infectious disease and brain health threats through innovative research protecting and optimizing warfighter lethality. WRAIR’s partners with a multitude of collaborators within the DoD and other U.S. government agencies as well as partners in industry, foreign militaries and government agencies, academia and non-governmental organizations (see also www.wrair.army.mil).

* Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

Zeitschriften
Wehrmedizinische Monatsschrift – Impressum/Datenschutz

Redaktion: Generalarzt a. D. Prof. Dr. med. Horst Peter Becker, MBA, Auf der Hardt 27, 56130 Bad Ems, Mobil +49 171 215 0901, E-Mail: hp.becker@cpm-verlag.de 

Herausgeber: Kommando Gesundheitsversorgung der Bundeswehr, Integrierte Kommunikation/Fachinformations- und Medienarbeit im Auftrag des Befehlshabers des Sanitätsdienstes der Bundeswehr, Von-Kuhl-Straße 50, 56070 Koblenz, Telefon: +49 261 896 12300, E-Mail: KdoGesVersBwIKoFaM@bundeswehr.org 

Wissenschaftliche Beratung: Die Begutachtung von Original- und Übersichtsarbeiten sowie Kasuistiken im Rahmen des Peer-Review-Verfahrens erfolgt durch in dem Fachgebiet des jeweiligen Beitrags wissenschaftlich ausgewiesene Expertinnen und/oder Experten, die – dem Einzelfall entsprechend – in Abstimmung zwischen Redaktion und Herausgeber ausgewählt und beauftragt werden.

Verlag: cpm Verlag GmbH, Carl-Zeiss-Str. 5, 53340 Meckenheim, Telefon +49 2225 8889–0, E-Mail: info@cpm-verlag.de; Geschäftsleitung: Tobias Ehlke; Objektleitung: Peter Geschwill; Produktionsleitung: Thorsten Menzel.

Druckversion: Druckvorstufe: PIC Crossmedia GmbH, Hitdorfer Straße 10, 40764 Langenfeld, E-Mail: info@pic-crossmedia.de; Druck: Bundesamt für Infrastruktur, Umweltschutz und Dienstleistungen der Bundeswehr (BAIUDBw), Zentraldruckerei Köln/Bonn.

Online-Version (E-Paper): Erstellung mit PIC MediaServer, PIC Crossmedia GmbH, Langenfeld; Erstellung mit PIC MediaServer, PIC Crossmedia GmbH, Langenfeld; E-Paper und Autorenhinweise sind unter wmm-online.de abrufbar

Rechtliche Hinweise: Die Zeitschrift (Druckversion und E-Paper) sowie alle enthaltenen Beiträge und Abbildungen sind in allen Publikationsformen urheberrechtlich geschützt. Jede Verwertung außerhalb der engen Grenzen des Urheberrechtsgesetzes ist ohne Zustimmung des Herausgebers unzulässig und strafbar. Dies gilt insbesondere für Vervielfältigungen, Übersetzungen, Mikroverfilmungen sowie die Einspeicherung und Verarbeitung in elektronischen Systemen.


Alle namentlich gezeichneten Beiträge – soweit sie nicht ausdrücklich mit einem * gekennzeichnet sind – geben die persönlichen Ansichten der Verfasser wieder. Sie entsprechen nicht zwingend den Auffassungen der Redaktion oder des Herausgebers. Manuskriptsendungen an die Redaktion erbeten. Erscheinungsweise mindestens achtmal im Jahr.


Für Mitglieder der Deutschen Gesellschaft für Wehrmedizin und Wehrpharmazie e. V. ist der Bezug der Zeitschrift im Mitgliedsbeitrag enthalten. Sanitätsoffiziere der Bundeswehr, die nicht Mitglieder der Deutschen Gesellschaft für Wehrmedizin und Wehrpharmazie e. V. sind, erhalten die „Wehrmedizinische Monatsschrift“ über ihre Dienststellen.

Datenschutz: Es gelten die Datenschutzbestimmungen der cpm Verlag GmbH, abrufbar unter https://cpm-verlag.com/datenschutzerklaerung/.